Estrella Immunopharma (ESLA)
NASDAQ:ESLA
ESLA Stock Chart & Stats
$1.88
-$0.08(-6.72%)
At close: 4:00 PM EST
$1.88
-$0.08(-6.72%)
Day’s Range― - ―
52-Week Range$0.78 - $3.15
Previous Close$1.15
Volume4.72K
Average Volume (3M)165.74K
Market Cap
$42.29M
Enterprise Value$41.54M
Total Cash (Recent Filing)$1.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding43,034,230
10 Day Avg. Volume298,509
30 Day Avg. Volume165,737
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)-5.54
Price to Sales (P/S)0.00
P/FCF Ratio-32.17
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Estrella Immunopharma News
ESLA FAQ
What was Estrella Immunopharma’s price range in the past 12 months?
Estrella Immunopharma lowest stock price was $0.78 and its highest was $3.15 in the past 12 months.
What is Estrella Immunopharma’s market cap?
Estrella Immunopharma’s market cap is $42.29M.
When is Estrella Immunopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Estrella Immunopharma’s earnings last quarter?
Currently, no data Available
Is Estrella Immunopharma overvalued?
According to Wall Street analysts Estrella Immunopharma’s price is currently Overvalued.
Does Estrella Immunopharma pay dividends?
Estrella Immunopharma does not currently pay dividends.
What is Estrella Immunopharma’s EPS estimate?
Estrella Immunopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Estrella Immunopharma have?
Estrella Immunopharma has 43,034,230 shares outstanding.
What happened to Estrella Immunopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Estrella Immunopharma?
Currently, no hedge funds are holding shares in ESLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Estrella Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 255.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.33%
12-Months-Change
Fundamentals
Return on Equity
167.91%
Trailing 12-Months
Asset Growth
49.62%
Trailing 12-Months
Company Description
Estrella Immunopharma
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Technical Analysis
Celularity
―
Aligos Therapeutics
―
BioAtla
―
Acrivon Therapeutics, Inc.
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
0.66% Insiders
1.11% Mutual Funds
9.52% Other Institutional Investors
87.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---